METTL3 and breast cancer: YTHDC1 binds to m6A-modified EGF mRNA and promotes EGF synthesis, suggesting that METTL3 and YTHDC1 together enhance HR and cell survival during doxorubicin treatment, leading to the development of drug resistance in breast cancer [47].